Effect of pharmacogenomics - oriented Dual Antiplatelet Therapy Followed by P2Y12 receptor inhibitors/Aspirin on Cardiovascular and Bleeding Events in ACS Patients: A Trial Protocol

Author:

Peng Hui1,Ji Longyu2,Lai Hongmei1,Tao Jing1,Li Guoqing1,Gao Jiong2,Wang Zhao1,Yao Juan1,Guo Zitong1,Xi’er Zulipiye1,Zhao Peng1,Shen Xin1,Gu Peipei1,Li Jie1,Yang Yining1

Affiliation:

1. People's Hospital of Xinjiang Uygur Autonomous Region

2. WuXi diagnostics Lab (Shanghai) Co.,Ltd

Abstract

Abstract

Dual antiplatelet therapy (DAPT) combined of aspirin and P2Y12 receptor inhibitors is the mainstay of treatment after acute coronary syndrome (ACS), but there are some problems remained to be explored, such as the duration of DAPT and choice of P2Y12 receptor inhibitors. This protocol is to evaluate the clinical benefit of pharmacogenomics (PGx)-based strategy of DAPT for ACS patients through a real-world study. A total of 6037 ACS patients are expected to be included in the study, with 3185 patients assigned to the PGx group and 3185 patients to the standard treatment group. The primary endpoint is major adverse cardiovascular events (MACE). The secondary endpoint is main efficacy indicators and composite outcome of stent thrombosis. The safety endpoint is major bleeding (BARC 2, 3, 4, 5) and fatal bleeding. We expect lower incidence of MACE and bleeding events in patients with genotype-guided treatment, compared to treatment as usual. Consequently, this protocol is expected to identify a genotype-based strategy of precise medication of antiplatelet therapy.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3